emerald-1 trial: improved pfs w/ durvalumab bevacizumab tace vs tace in hepatocellular carcinoma
Published 7 months ago • 163 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
1:03
phase iii emerald-1: bevacizumab and durvalumab with tace improves pfs in unresectable hcc
-
0:55
exploring durvalumab bevacizumab tace in hepatocellular carcinoma: emerald-1 insights
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc
-
2:09
safey findings of emerald-1: durvalumab, bevacizumab and tace in hcc
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
20:15
ablation, chemoembolization and radioembolization in primary liver cancer / hepatocellular carcinoma
-
17:35
best practices for hit-to-lead - case study: malt1 inhibitors
-
8:43
results from monumental-1: first-in-human study of talquetamab in pts with rr multiple myeloma
-
7:23
durvalumab plus bevacizumab, added to tace, shows benefit for unresectable hepatocellular carcinoma
-
3:38
emerald-1 trial in hcc
-
4:24
emuc18: stampede trial
-
33:51
dr. oren gilad, ph.d. - ceo, aprea therapeutics - forging new pathways in the fight against cancer
-
1:00
trial of durvalumab for bladder cancer
-
2:49
first-in-human trial of medi1191 plus durvalumab in patients with advanced solid tumors
-
3:00
dutreneo trial
-
0:52
drp-104 with durvalumab in fibrolamellar hepatocellular carcinoma
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
4:20
coviprotect test: an extra step for safety.
-
4:18
phase 3 recourse trial of tas-102 vs placebo
-
12:15
proton beam radiotherapy vs. tace for hepatocellular carcinoma, with dr. david a. bush
-
1:40
safety results from phase 3b strong trial of durvalumab in patients with urinary tract carcinoma